Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
INCY
Incyte Corp.
$86.85
Login to see Incyte Corp. (INCY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Risk Analysis
Downgraded on weak valued
Technical Indicators
Aroon crosses up
Chart
$85.6 (+1.46%)
$69.98 (+24.11%)
$61.01 (+42.35%)
$66.39 (+30.82%)
INCY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
INCY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Eps growth
Rating
Rating
Downgraded on weak valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
INCY Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
INCY Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayINCY Earnings
The TTM reflects 12-month period, providing review of INCY financial performance.
The company financial health has moderately improved over the past year
Financial Score
What is INCY current stock price?
What are INCY stock strengths?
What risks are associated with INCY stock?
When is INCY next earnings report?
What is INCY market cap and volume?
What is INCY's current Stock IQ?
Should I buy INCY stock right now?
Is INCY a Strong Buy right now?
What does a 'Strong Buy' rating mean for INCY?
What does a 'Strong Sell' rating mean for INCY?
What factors influence INCY's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
INCY
Incyte Corp.
Current Price
$86.85
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Risk Analysis
Downgraded on weak valued
Technical Indicators
Aroon crosses up
Login to unlock Incyte Corp. (INCY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$85.6 (+1.46%)
$69.98 (+24.11%)
$61.01 (+42.35%)
$66.39 (+30.82%)
INCY Analysts Opinion
INCY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Eps growth
Rating
Rating
Downgraded on weak valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
INCY Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
INCY Street view is extremely bullish and have positive views on the near-term outlook
INCY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayINCY Earnings
The TTM data reflects the most recent 12-month period, providing overview of INCY financial performance.
INCY Financial Health
The company financial health has moderately improved over the past year
Financial Score
INCY Latest Analysis
Jim Cramer Calls Incyte Way Too Cheap. Incyte Corporation (NASDAQ:INCY) is one of the relatively cheap S&.P 500 stocks Jim Cramer talked about. Cramer mentioned that it is the healthcare stock that stands out to him. He stated: What else? Now we know healthcare has been mostly a wasteland this year which is why only four stocks in the group passed the [….]
Thu Sep 25, 2025
Incyte stock price target raised to $81 from $72 at RBC Capital.
Wed Sep 24, 2025
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings). Analysts'. ratings for Incyte (NASDAQ:) over the last quarter vary from ish to bearish as provided by 11 analysts.The table below provides a concise overview of recent ratings by analysts offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.2261000000101001241000100Providing deeper insights analysts have established 12-month price targ
Fri Sep 19, 2025
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream . Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis marking its third United States approval and boosting sales momentum.
Fri Sep 19, 2025
FDA Expands Incytes Opzelura Approval To Treat Atopic Dermatitis In Children. The United States Food and Drug Administration (FDA) on Thursday approved ) announced Opzelura (ruxolitinib) cream 1.5% for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease is not well controlled with topical prescription therapies or when those .The FDA approval of the supplemental New Drug Applicat
Fri Sep 19, 2025
Incyte gets FDA nod for Opzelura cream in atopic dermatitis treatment.
Thu Sep 18, 2025
Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development. Former Pfizer BenevolentAI Incyte and AMAG executives join to strengthen clinical technology financial and scientific leadership as company scales its AI-native pharma model NEW YORK Sept. 18 2025 /PRNewswire/ -- Formation Bio the AI-native pharmaceutical company revolutionizing...
Thu Sep 18, 2025
Incyte Reaches Analyst Target Price. In recent trading shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18 changing hands for $84.80/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react: downgrade on v
Thu Sep 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
INCY Stock trends
INCY Stock performance
INCY Stock analysis
INCY investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings